Literature DB >> 11094332

Kininogen-cytokeratin 1 interactions in endothelial cell biology.

Z Shariat-Madar1, A H Schmaier.   

Abstract

This review brings available data together to put in perspective the binding properties of high molecular weight kininogen (HK) to cytokeratin 1 (CK1) to direct future investigations. We summarize our knowledge of the structure and function of HK and discuss the influence of HK on the biologic activities of the plasma kallikrein/kinin system. To better understand the role of HK in regulating the activation of the kallikrein/kinin system, we discuss the interaction of HK with endothelial cell CK1 and its influence on prekallikrein activation. Last, we address the question on how a cytoskeletal protein could be a membrane-binding site and its possible role in disease states.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11094332     DOI: 10.1016/s1050-1738(00)00028-1

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  4 in total

1.  Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system.

Authors:  Joshua M Astern; William F Pendergraft; Ronald J Falk; J Charles Jennette; Alvin H Schmaier; Fakhri Mahdi; Gloria A Preston
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

2.  High molecular weight kininogen activates B2 receptor signaling pathway in human vascular endothelial cells.

Authors:  Dhaval Kolte; Noah Osman; Jia Yang; Zia Shariat-Madar
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

Review 3.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

Review 4.  A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019.

Authors:  Chiara Colarusso; Michela Terlizzi; Aldo Pinto; Rosalinda Sorrentino
Journal:  Br J Pharmacol       Date:  2020-06-30       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.